Sanofi SA (SNY) Stock Price Today
Aura AI Summary
Key Stats
- $99.64BMarket Cap
- 2,011,327Volume
- HealthSector
- $52.3452W High
- $39.1252W Low
- 95 DaysTypical Hold Time
- $118.97BEnterprise Value
- 5.82%Div Yield
- -Trading Activity
Track Sanofi SA (SNY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Sanofi SA has traded between a low of $39.12 and a high of $52.34, highlighting its annual price range. Buy and sell Sanofi SA shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Most Recent News
Norsk Hydro invites investors to its London investor day on Nov 25, with CEO and CFO presentations.
Norsk Hydro has announced an investor day event scheduled for November 25, 2026, in London at 30 Euston Square. The event will feature presentations and Q&A sessions with the CEO and CFO, followed by lunch and roundtable discussions exclusively for s...

Norsk Hydro invites investors to its London Investor Day on Nov 25, 2026, with virtual attendance option.
Norsk Hydro has announced its Investor Day event scheduled for November 25, 2026, in London, with an option to join virtually. The event will feature presentations and Q&A sessions with the CEO and CFO, followed by a roundtable exclusively for sell-s...

Microbiotica's MB097 shows safety and promising efficacy in advanced melanoma Phase 1b trial with KEYTRUDA.
Microbiotica presented positive Phase 1b trial results for MB097, a precision microbiome therapy combined with KEYTRUDA, in advanced melanoma patients resistant to anti-PD-1 therapy. The trial showed MB097 was safe, well tolerated, and led to signifi...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.